These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16710907)

  • 21. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
    Bernier J; Schneider D
    Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
    Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
    [No Abstract]   [Full Text] [Related]  

  • 23. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant.
    Mydin AR; Armstrong JG
    Clin Oncol (R Coll Radiol); 2007 Jun; 19(5):365-6. PubMed ID: 17379490
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
    Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
    Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
    Valeriani M; Muni R; Osti MF; De Sanctis V; Minniti G; Ardito F; Maurizi Enrici R
    Radiol Med; 2012 Feb; 117(1):125-32. PubMed ID: 21892718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
    Le QT; Raben D
    Semin Radiat Oncol; 2009 Jan; 19(1):53-62. PubMed ID: 19028346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promising new advances in head and neck radiotherapy.
    Harari PM
    Ann Oncol; 2005; 16 Suppl 6():vi13-vi19. PubMed ID: 15987991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
    Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
    Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of current treatment practices for carcinoma of the head and neck.
    Modi BJ; Knab B; Feldman LE; Mundt AJ; Yao M; Pytynia KB; Epstein J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1143-55. PubMed ID: 15957968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
    Budach W; Bölke E; Homey B
    N Engl J Med; 2007 Aug; 357(5):514-5. PubMed ID: 17671265
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune biomarkers of anti-EGFR monoclonal antibody therapy.
    Trivedi S; Concha-Benavente F; Srivastava RM; Jie HB; Gibson SP; Schmitt NC; Ferris RL
    Ann Oncol; 2015 Jan; 26(1):40-47. PubMed ID: 24997207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
    Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
    Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rash conclusions from a phase 3 study of cetuximab?
    Harrington KJ
    Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
    [No Abstract]   [Full Text] [Related]  

  • 37. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.
    Wheeler RH; Spencer S; Buchsbaum D; Robert F
    Curr Opin Oncol; 1999 May; 11(3):187-90. PubMed ID: 10328593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
    Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
    J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck.
    Chan AK; Sanghera P; Choo BA; McConkey C; Mehanna H; Parmar S; Pracy P; Glaholm J; Hartley A
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):34-9. PubMed ID: 20863676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.